Study of 90Y-DOTA-hLL2 as a Consolidation Therapy After R-CHOP in Patients With Diffuse Large B-cell Lymphoma
Phase II Study of Evaluation of Fractionated Radio-immunotherapy With 90Y-DOTA-hLL2 as a Consolidation Therapy After First Line of Chemotherapy in Patients Older Than 60 With Disseminated Diffuse Large B-cell Lymphoma
Sponsor: French Innovative Leukemia Organisation
Terminated
completed recruitment of patients on 15 december 2010
Other terminated trials from French Innovative Leukemia Organisation
- Essential Thrombocythemia · Phase PHASE2/PHASE3 · Jun 2021
- B-cell Chronic Lymphocytic Leukemia (B-CLL) · Phase PHASE2 · Apr 2018
- B Cell Lymphoma · Phase PHASE3 · Feb 2017
- Lymphoma · Phase PHASE3 · Mar 2016
See all terminations from French Innovative Leukemia Organisation
Other B-cell Lymphoma trials with similar outcome
A PHASE2 clinical study on B-cell Lymphoma, this trial is terminated or withdrawn. The trial is conducted by French Innovative Leukemia Organisation and has accumulated 6 data snapshots since 2007. Oncology trials at this stage typically focus on safety, tolerability, and early efficacy signals.
Status Flow
Change History
6 versions recorded-
Sep 2024 — Present [monthly]
Terminated PHASE2
-
Jul 2024 — Sep 2024 [monthly]
Terminated PHASE2
-
Jan 2021 — Jul 2024 [monthly]
Terminated PHASE2
-
Jun 2018 — Jan 2021 [monthly]
Terminated PHASE2
-
May 2018 — Jun 2018 [monthly]
Terminated PHASE2
▶ Show 1 earlier version
-
Jan 2017 — May 2018 [monthly]
Terminated PHASE2
First recorded
Oct 2007
Trial started
Per CT.gov start date — pre-dates our first snapshot
Eligibility Summary
No eligibility information available.
Contact Information
- French Innovative Leukemia Organisation
For direct contact, visit the study record on ClinicalTrials.gov .